A Study of LY3435151 in Participants With Solid Tumors
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Solid Tumor|Triple-negative Breast Cancer|Gastric Adenocarcinoma|Head and Neck Squamous Cell Carcinoma|Cervical Carcinoma|High Grade Serous Ovarian Carcinoma|Hepatocellular Carcinoma|Undifferentiated Pleomorphic Sarcoma|Leiomyosarcoma
Interventions: DRUG: LY3435151|DRUG: Pembrolizumab
Sponsor: Eli Lilly and Company